Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 20/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19100908 | 0.90 | PTGS2 (0.44) | PTGS2 | |
| SCHEMBL16893648 | 0.82 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL5566588 | 0.79 | PTGS2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL16893933 | 0.73 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL5565897 | 0.71 | PTGS2 (0.35) | PTGS2PTGS1 | |
| SCHEMBL5559994 | 0.70 | PTGS2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL16893618 | 0.70 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL16893786 | 0.68 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL16893788 | 0.68 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL5566105 | 0.67 | PTGS2 (0.35) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | ARG1, ARGLU1, CGAS | PTGS2 1336/4885PTGS1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.